| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Contrast Media | 31 | 2025 | 459 | 6.530 |
Why?
|
| Nanoparticles | 22 | 2025 | 267 | 4.260 |
Why?
|
| Liposomes | 22 | 2019 | 196 | 2.040 |
Why?
|
| X-Ray Microtomography | 7 | 2025 | 96 | 1.790 |
Why?
|
| Gadolinium | 7 | 2019 | 110 | 1.750 |
Why?
|
| Tomography, X-Ray Computed | 13 | 2025 | 2041 | 1.660 |
Why?
|
| Iodine | 5 | 2023 | 22 | 1.620 |
Why?
|
| Magnetic Resonance Imaging | 14 | 2025 | 3696 | 1.480 |
Why?
|
| Triiodobenzoic Acids | 5 | 2021 | 30 | 1.290 |
Why?
|
| Placenta | 5 | 2025 | 511 | 1.220 |
Why?
|
| Alzheimer Disease | 3 | 2024 | 835 | 1.000 |
Why?
|
| Plaque, Atherosclerotic | 3 | 2022 | 144 | 0.860 |
Why?
|
| Phantoms, Imaging | 5 | 2022 | 128 | 0.810 |
Why?
|
| Animals | 53 | 2025 | 33185 | 0.780 |
Why?
|
| Aortic Rupture | 2 | 2021 | 114 | 0.770 |
Why?
|
| Plaque, Amyloid | 2 | 2020 | 72 | 0.760 |
Why?
|
| Aortography | 2 | 2021 | 158 | 0.750 |
Why?
|
| Mice | 37 | 2025 | 17671 | 0.710 |
Why?
|
| Image Enhancement | 4 | 2010 | 160 | 0.670 |
Why?
|
| Aorta | 3 | 2021 | 518 | 0.660 |
Why?
|
| Sarcoma | 2 | 2022 | 205 | 0.650 |
Why?
|
| Brain Neoplasms | 5 | 2019 | 1224 | 0.650 |
Why?
|
| Drug Delivery Systems | 4 | 2019 | 204 | 0.650 |
Why?
|
| Amyloid | 1 | 2020 | 69 | 0.640 |
Why?
|
| Cognitive Dysfunction | 1 | 2024 | 285 | 0.640 |
Why?
|
| Lung Neoplasms | 3 | 2016 | 1493 | 0.620 |
Why?
|
| Computed Tomography Angiography | 1 | 2021 | 209 | 0.610 |
Why?
|
| Disease Models, Animal | 13 | 2025 | 4442 | 0.610 |
Why?
|
| Aortic Aneurysm | 1 | 2021 | 220 | 0.560 |
Why?
|
| Mammary Neoplasms, Animal | 2 | 2016 | 134 | 0.520 |
Why?
|
| Blood-Brain Barrier | 3 | 2019 | 140 | 0.520 |
Why?
|
| Atherosclerosis | 2 | 2022 | 929 | 0.480 |
Why?
|
| Neuroblastoma | 2 | 2022 | 539 | 0.480 |
Why?
|
| Dog Diseases | 1 | 2016 | 58 | 0.470 |
Why?
|
| Liver Neoplasms | 3 | 2022 | 1351 | 0.410 |
Why?
|
| Antineoplastic Agents | 4 | 2016 | 1758 | 0.400 |
Why?
|
| Drug Carriers | 5 | 2019 | 116 | 0.380 |
Why?
|
| Magnetic Resonance Angiography | 3 | 2009 | 160 | 0.380 |
Why?
|
| Photons | 2 | 2025 | 55 | 0.360 |
Why?
|
| Glioblastoma | 2 | 2015 | 331 | 0.340 |
Why?
|
| Mice, Inbred C57BL | 7 | 2025 | 4513 | 0.320 |
Why?
|
| Indocyanine Green | 3 | 2023 | 53 | 0.320 |
Why?
|
| Gadolinium DTPA | 2 | 2007 | 47 | 0.320 |
Why?
|
| Rats | 7 | 2020 | 3394 | 0.310 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2011 | 236 | 0.300 |
Why?
|
| Neovascularization, Pathologic | 4 | 2019 | 234 | 0.300 |
Why?
|
| Hepatoblastoma | 2 | 2022 | 186 | 0.300 |
Why?
|
| Tumor Burden | 3 | 2016 | 229 | 0.300 |
Why?
|
| Theranostic Nanomedicine | 2 | 2020 | 8 | 0.290 |
Why?
|
| Apolipoproteins E | 3 | 2025 | 184 | 0.290 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2012 | 316 | 0.290 |
Why?
|
| Aortic Diseases | 2 | 2025 | 186 | 0.280 |
Why?
|
| Tumor Microenvironment | 2 | 2020 | 628 | 0.280 |
Why?
|
| Optical Imaging | 2 | 2018 | 72 | 0.270 |
Why?
|
| Spine | 1 | 2007 | 137 | 0.240 |
Why?
|
| Peptide Fragments | 2 | 2020 | 756 | 0.240 |
Why?
|
| Cell Line, Tumor | 8 | 2022 | 3499 | 0.240 |
Why?
|
| Nanomedicine | 3 | 2020 | 27 | 0.240 |
Why?
|
| Moyamoya Disease | 1 | 2025 | 42 | 0.230 |
Why?
|
| Neoplasms | 5 | 2020 | 2856 | 0.230 |
Why?
|
| Oxidative Phosphorylation | 1 | 2025 | 126 | 0.220 |
Why?
|
| Ferrosoferric Oxide | 1 | 2025 | 27 | 0.220 |
Why?
|
| Cardiovascular Diseases | 3 | 2025 | 2036 | 0.220 |
Why?
|
| Physical Conditioning, Animal | 1 | 2025 | 83 | 0.220 |
Why?
|
| Mice, Nude | 6 | 2019 | 708 | 0.210 |
Why?
|
| Humans | 26 | 2025 | 127201 | 0.210 |
Why?
|
| Mice, Transgenic | 3 | 2022 | 2311 | 0.210 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2025 | 177 | 0.210 |
Why?
|
| Cadmium Compounds | 1 | 2023 | 1 | 0.200 |
Why?
|
| Actins | 1 | 2025 | 311 | 0.200 |
Why?
|
| Quantum Dots | 1 | 2023 | 15 | 0.200 |
Why?
|
| Receptors, Cell Surface | 1 | 2005 | 422 | 0.200 |
Why?
|
| Folic Acid | 1 | 2005 | 282 | 0.190 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2021 | 727 | 0.190 |
Why?
|
| Placenta Accreta | 1 | 2025 | 163 | 0.190 |
Why?
|
| Integrin alphaVbeta3 | 2 | 2019 | 17 | 0.190 |
Why?
|
| Adventitia | 1 | 2022 | 5 | 0.190 |
Why?
|
| Nanotechnology | 2 | 2014 | 48 | 0.180 |
Why?
|
| Tissue Distribution | 2 | 2020 | 363 | 0.180 |
Why?
|
| Positron-Emission Tomography | 1 | 2024 | 291 | 0.180 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2022 | 76 | 0.180 |
Why?
|
| Mouth Neoplasms | 1 | 2023 | 93 | 0.180 |
Why?
|
| Models, Biological | 2 | 2011 | 1373 | 0.180 |
Why?
|
| Female | 18 | 2025 | 68579 | 0.170 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2012 | 169 | 0.170 |
Why?
|
| Oxadiazoles | 1 | 2021 | 25 | 0.170 |
Why?
|
| Molecular Imaging | 2 | 2013 | 60 | 0.170 |
Why?
|
| Dilatation, Pathologic | 1 | 2021 | 80 | 0.170 |
Why?
|
| Pregnancy | 5 | 2025 | 7380 | 0.170 |
Why?
|
| Research Design | 1 | 2025 | 694 | 0.170 |
Why?
|
| Presenilin-1 | 1 | 2020 | 57 | 0.170 |
Why?
|
| Macaca fascicularis | 1 | 2020 | 81 | 0.170 |
Why?
|
| Doxorubicin | 2 | 2019 | 286 | 0.170 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2020 | 48 | 0.170 |
Why?
|
| Bone Morphogenetic Protein 4 | 1 | 2020 | 36 | 0.170 |
Why?
|
| Thrombospondin 1 | 1 | 2020 | 21 | 0.170 |
Why?
|
| Intracranial Arteriovenous Malformations | 1 | 2020 | 33 | 0.160 |
Why?
|
| Angiotensin II | 1 | 2021 | 133 | 0.160 |
Why?
|
| Aorta, Thoracic | 1 | 2025 | 534 | 0.160 |
Why?
|
| Early Diagnosis | 1 | 2021 | 187 | 0.160 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2017 | 1127 | 0.160 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2020 | 89 | 0.160 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2020 | 1596 | 0.160 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2020 | 50 | 0.160 |
Why?
|
| Radiographic Image Enhancement | 2 | 2011 | 40 | 0.160 |
Why?
|
| Carrier Proteins | 1 | 2005 | 1011 | 0.160 |
Why?
|
| Fatty Acids | 1 | 2022 | 351 | 0.160 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2020 | 130 | 0.160 |
Why?
|
| Heterografts | 2 | 2017 | 190 | 0.150 |
Why?
|
| Cytosol | 1 | 2019 | 138 | 0.150 |
Why?
|
| Blood Volume | 1 | 2019 | 71 | 0.150 |
Why?
|
| Silicon Dioxide | 1 | 2019 | 31 | 0.150 |
Why?
|
| Fibronectins | 1 | 2019 | 99 | 0.150 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2019 | 20 | 0.150 |
Why?
|
| Piperazines | 1 | 2021 | 256 | 0.150 |
Why?
|
| Diet, High-Fat | 1 | 2021 | 239 | 0.150 |
Why?
|
| Fluorine | 1 | 2018 | 14 | 0.150 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 2233 | 0.150 |
Why?
|
| Endothelial Cells | 2 | 2020 | 504 | 0.150 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2019 | 123 | 0.150 |
Why?
|
| Hindlimb | 1 | 2018 | 73 | 0.140 |
Why?
|
| Papillomavirus Infections | 1 | 2023 | 386 | 0.140 |
Why?
|
| Fluorocarbons | 1 | 2018 | 61 | 0.140 |
Why?
|
| Integrin alpha4beta1 | 1 | 2018 | 26 | 0.140 |
Why?
|
| Angiography | 1 | 2018 | 192 | 0.140 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2017 | 65 | 0.140 |
Why?
|
| Brain | 4 | 2024 | 3039 | 0.140 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2021 | 946 | 0.130 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2021 | 588 | 0.130 |
Why?
|
| Skull | 1 | 2018 | 147 | 0.130 |
Why?
|
| Neoplasm Transplantation | 1 | 2017 | 361 | 0.130 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2025 | 684 | 0.130 |
Why?
|
| Cell Cycle Proteins | 1 | 2021 | 677 | 0.130 |
Why?
|
| Echo-Planar Imaging | 1 | 2016 | 21 | 0.120 |
Why?
|
| Magnetite Nanoparticles | 1 | 2016 | 8 | 0.120 |
Why?
|
| In Vitro Techniques | 1 | 2017 | 824 | 0.120 |
Why?
|
| Mice, Inbred BALB C | 3 | 2016 | 1001 | 0.120 |
Why?
|
| Ligands | 3 | 2019 | 477 | 0.120 |
Why?
|
| Mice, Knockout | 5 | 2025 | 3711 | 0.120 |
Why?
|
| Organometallic Compounds | 2 | 2016 | 109 | 0.120 |
Why?
|
| Membrane Proteins | 2 | 2020 | 1569 | 0.120 |
Why?
|
| Time Factors | 4 | 2021 | 6160 | 0.120 |
Why?
|
| Dogs | 1 | 2016 | 614 | 0.110 |
Why?
|
| Disease Progression | 1 | 2021 | 2117 | 0.110 |
Why?
|
| DNA | 1 | 2019 | 1421 | 0.110 |
Why?
|
| Ferric Compounds | 3 | 2020 | 38 | 0.110 |
Why?
|
| Neoplasm Micrometastasis | 1 | 2013 | 13 | 0.110 |
Why?
|
| MicroRNAs | 1 | 2020 | 873 | 0.100 |
Why?
|
| Male | 10 | 2025 | 62767 | 0.100 |
Why?
|
| Nanocapsules | 1 | 2013 | 8 | 0.100 |
Why?
|
| Mammary Glands, Animal | 1 | 2016 | 446 | 0.100 |
Why?
|
| Liver | 2 | 2021 | 1765 | 0.100 |
Why?
|
| Microvessels | 1 | 2013 | 60 | 0.100 |
Why?
|
| Fetus | 1 | 2016 | 578 | 0.100 |
Why?
|
| Uterus | 1 | 2016 | 532 | 0.090 |
Why?
|
| Neoplasms, Experimental | 1 | 2013 | 203 | 0.090 |
Why?
|
| Particle Size | 2 | 2009 | 133 | 0.090 |
Why?
|
| Coordination Complexes | 1 | 2011 | 9 | 0.090 |
Why?
|
| Cerebrovascular Circulation | 1 | 2015 | 460 | 0.090 |
Why?
|
| Drug Compounding | 1 | 2011 | 39 | 0.090 |
Why?
|
| Signal Transduction | 2 | 2021 | 4481 | 0.090 |
Why?
|
| Aptamers, Nucleotide | 1 | 2011 | 34 | 0.080 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2011 | 379 | 0.080 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2011 | 276 | 0.080 |
Why?
|
| Surface Properties | 1 | 2009 | 81 | 0.080 |
Why?
|
| Spectroscopy, Near-Infrared | 2 | 2023 | 153 | 0.080 |
Why?
|
| Cerebral Arteries | 1 | 2009 | 80 | 0.080 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2009 | 590 | 0.080 |
Why?
|
| Iopamidol | 1 | 2009 | 3 | 0.080 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2017 | 968 | 0.070 |
Why?
|
| Lung | 1 | 2016 | 1522 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 1232 | 0.070 |
Why?
|
| Mammography | 1 | 2009 | 129 | 0.070 |
Why?
|
| Iohexol | 1 | 2007 | 17 | 0.070 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 2007 | 6 | 0.070 |
Why?
|
| Diagnosis, Differential | 1 | 2012 | 1863 | 0.070 |
Why?
|
| Spinal Nerve Roots | 1 | 2007 | 17 | 0.060 |
Why?
|
| Cardiology | 1 | 2012 | 488 | 0.060 |
Why?
|
| Veins | 1 | 2007 | 99 | 0.060 |
Why?
|
| Vena Cava, Inferior | 1 | 2007 | 99 | 0.060 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2007 | 112 | 0.060 |
Why?
|
| Artifacts | 1 | 2007 | 103 | 0.060 |
Why?
|
| Arteries | 1 | 2007 | 196 | 0.060 |
Why?
|
| Aged | 1 | 2024 | 20414 | 0.060 |
Why?
|
| Niacinamide | 1 | 2025 | 30 | 0.060 |
Why?
|
| Folate Receptors, GPI-Anchored | 1 | 2005 | 54 | 0.060 |
Why?
|
| Fibrinolytic Agents | 1 | 2007 | 198 | 0.060 |
Why?
|
| Binding, Competitive | 1 | 2005 | 153 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2007 | 2074 | 0.060 |
Why?
|
| Polyethylene Glycols | 1 | 2006 | 240 | 0.060 |
Why?
|
| Pulmonary Embolism | 1 | 2007 | 184 | 0.050 |
Why?
|
| Glycolysis | 1 | 2025 | 168 | 0.050 |
Why?
|
| Apolipoprotein E3 | 1 | 2023 | 8 | 0.050 |
Why?
|
| Apolipoprotein E2 | 1 | 2023 | 16 | 0.050 |
Why?
|
| Breast Neoplasms | 2 | 2013 | 2583 | 0.050 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2025 | 226 | 0.050 |
Why?
|
| Apolipoprotein E4 | 1 | 2023 | 47 | 0.050 |
Why?
|
| Apoptosis | 2 | 2021 | 1811 | 0.050 |
Why?
|
| Gallium | 1 | 2023 | 1 | 0.050 |
Why?
|
| Tellurium | 1 | 2023 | 2 | 0.050 |
Why?
|
| Arsenicals | 1 | 2023 | 14 | 0.050 |
Why?
|
| Bismuth | 1 | 2023 | 83 | 0.050 |
Why?
|
| N-Myc Proto-Oncogene Protein | 1 | 2022 | 56 | 0.050 |
Why?
|
| Vimentin | 1 | 2022 | 63 | 0.050 |
Why?
|
| Microscopy, Fluorescence | 2 | 2013 | 308 | 0.040 |
Why?
|
| Cell Movement | 1 | 2025 | 851 | 0.040 |
Why?
|
| Fluorescent Dyes | 1 | 2023 | 248 | 0.040 |
Why?
|
| ADAM10 Protein | 1 | 2020 | 13 | 0.040 |
Why?
|
| Activin Receptors, Type II | 1 | 2020 | 31 | 0.040 |
Why?
|
| Monoterpenes | 1 | 2020 | 7 | 0.040 |
Why?
|
| Heart | 1 | 2025 | 650 | 0.040 |
Why?
|
| Activin Receptors, Type I | 1 | 2020 | 33 | 0.040 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2020 | 62 | 0.040 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2020 | 50 | 0.040 |
Why?
|
| Lymphocytes | 1 | 2022 | 355 | 0.040 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2020 | 87 | 0.040 |
Why?
|
| Mitochondria | 1 | 2025 | 730 | 0.040 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2020 | 126 | 0.040 |
Why?
|
| tau Proteins | 1 | 2022 | 236 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2021 | 372 | 0.040 |
Why?
|
| Genotype | 1 | 2025 | 2598 | 0.040 |
Why?
|
| Signal-To-Noise Ratio | 1 | 2018 | 38 | 0.040 |
Why?
|
| Placentation | 1 | 2019 | 58 | 0.040 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2018 | 59 | 0.040 |
Why?
|
| Limit of Detection | 1 | 2018 | 74 | 0.040 |
Why?
|
| Solubility | 1 | 2018 | 123 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2021 | 826 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2025 | 1854 | 0.030 |
Why?
|
| Molecular Conformation | 1 | 2018 | 94 | 0.030 |
Why?
|
| Killer Cells, Natural | 1 | 2020 | 333 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2019 | 985 | 0.030 |
Why?
|
| Hep G2 Cells | 1 | 2017 | 90 | 0.030 |
Why?
|
| Rats, Inbred F344 | 2 | 2009 | 98 | 0.030 |
Why?
|
| Chickens | 1 | 2017 | 284 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2017 | 289 | 0.030 |
Why?
|
| Models, Animal | 1 | 2019 | 452 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2018 | 566 | 0.030 |
Why?
|
| Meglumine | 1 | 2016 | 16 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2017 | 570 | 0.030 |
Why?
|
| Cattle | 1 | 2017 | 539 | 0.030 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2016 | 80 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2020 | 741 | 0.030 |
Why?
|
| Gestational Age | 1 | 2019 | 1188 | 0.030 |
Why?
|
| Models, Molecular | 1 | 2018 | 1058 | 0.030 |
Why?
|
| Protein Binding | 1 | 2018 | 1663 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 1932 | 0.030 |
Why?
|
| Subtraction Technique | 1 | 2013 | 36 | 0.030 |
Why?
|
| Motion | 1 | 2013 | 39 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2015 | 636 | 0.020 |
Why?
|
| Biomarkers | 1 | 2022 | 3234 | 0.020 |
Why?
|
| Neuroimaging | 1 | 2016 | 361 | 0.020 |
Why?
|
| Microcirculation | 1 | 2013 | 102 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2014 | 280 | 0.020 |
Why?
|
| Breast | 1 | 2013 | 208 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2019 | 2397 | 0.020 |
Why?
|
| Whole Body Imaging | 1 | 2012 | 30 | 0.020 |
Why?
|
| Magnetics | 1 | 2011 | 29 | 0.020 |
Why?
|
| Hydrodynamics | 1 | 2011 | 29 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2021 | 4976 | 0.020 |
Why?
|
| Amides | 1 | 2011 | 89 | 0.020 |
Why?
|
| Sulfhydryl Compounds | 1 | 2011 | 55 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2011 | 423 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2013 | 755 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2011 | 106 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2013 | 797 | 0.020 |
Why?
|
| Macrophages | 1 | 2013 | 640 | 0.020 |
Why?
|
| Carcinoma | 1 | 2011 | 279 | 0.020 |
Why?
|
| Cell Line | 1 | 2013 | 2565 | 0.020 |
Why?
|
| Blood | 1 | 2007 | 99 | 0.020 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2006 | 31 | 0.020 |
Why?
|
| Rabbits | 1 | 2007 | 626 | 0.020 |
Why?
|
| Nanostructures | 1 | 2006 | 58 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2011 | 2897 | 0.010 |
Why?
|
| Radiography, Thoracic | 1 | 2006 | 148 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2021 | 14444 | 0.010 |
Why?
|
| Adult | 1 | 2025 | 30513 | 0.010 |
Why?
|
| Pulmonary Artery | 1 | 2007 | 442 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 2891 | 0.010 |
Why?
|